TY - JOUR
T1 - Height, selected genetic markers and prostate cancer risk
T2 - Results from the PRACTICAL consortium
AU - Lophatananon, Artitaya
AU - Stewart-Brown, Sarah
AU - Kote-Jarai, Zsofia
AU - Olama, Ali Amin Al
AU - Garcia, Sara Benlloch
AU - Neal, David E.
AU - Hamdy, Freddie C.
AU - Donovan, Jenny L.
AU - Giles, Graham G.
AU - Fitzgerald, Liesel M.
AU - Southey, Melissa C.
AU - Pharoah, Paul
AU - Pashayan, Nora
AU - Gronberg, Henrik
AU - Aly, Markus
AU - Stanford, Janet L.
AU - Brenner, Hermann
AU - Dieffenbach, Aida K.
AU - Arndt, Volker
AU - Park, Jong Y.
AU - Lin, Hui Yi
AU - Sellers, Thomas
AU - Slavov, Chavdar
AU - Kaneva, Radka
AU - Mitev, Vanio
AU - Batra, Jyotsna
AU - Spurdle, Amanda
AU - Clements, Judith A.
AU - APCB BioResource
AU - The PRACTICAL consortium
AU - Easton, Douglas
AU - Eeles, Rosalind A.
AU - Muir, Kenneth
PY - 2017/8/22
Y1 - 2017/8/22
N2 - Background:Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.Methods:We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions.Results:The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01-1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group.Conclusions:There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.
AB - Background:Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.Methods:We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions.Results:The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01-1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group.Conclusions:There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.
UR - http://www.scopus.com/inward/record.url?scp=85028312750&partnerID=8YFLogxK
U2 - 10.1038/bjc.2017.231
DO - 10.1038/bjc.2017.231
M3 - Article
C2 - 28765617
AN - SCOPUS:85028312750
VL - 117
SP - 734
EP - 743
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 5
ER -